Rekomendacje diagnostyczne i terapeutyczne dla przewlekłej białaczki limfocytowej w 2025 roku — Raport Grupy Roboczej PTHiT i PALG-CLL
Hematologia — Edukacja · 2025
DOI: 10.5603/ahp.106584 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hematologia — Edukacja, 2025. Verfasst von Iwona Hus und 5 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Chronic lymphocytic leukemia (CLL) is a disease of the elderly, with a median age at diagnosis of about 70 years. Thenatural course of the disease varies greatly, and patients with non-progressive and asymptomatic leukemia do notrequire therapy. However, treatment is indicated in advanced and/or progressive CLL. The results of CLL treatmenthave improved significantly in recent years, mainly due to the introduction of new and more effective drugs, includingB-cell receptor (BCR) inhibitors and B-cell lymphoma 2 (BCL2) inhibitors. These new drugs are used continuously asmonotherapy, or in combination regimens for specified periods. Venetoclax in combination with anti-CD20 antibodiesis administered for 24 or 12 months (with rituximab and obinutuzumab, respectively), while the combination ofvenetoclax and ibrutinib is delivered in fifteen 28-day cycles. The choice of treatment protocol should largely dependon the assessment of 17p deletion/TP53 mutation and, in the first line of treatment, on the immunoglobulin variableheavy chain (IGVH) mutation status. In recent years, the role of immunochemotherapy in the treatment of CLLpatients has become marginal. Patients presenting with indications for treatment should receive the novel targetedtherapies, which are currently available in Poland under the National Health Fund’s drug program, in the first as wellas in the subsequent treatment lines. This article provides an update on the standards of practice for diagnosis andtherapy in 2025.
Zitieren
APA
Hus, I., Giannopoulos, K., Jamroziak, K., Wołowiec, D., Roliński, J., & Robak, T. (2025). Rekomendacje diagnostyczne i terapeutyczne dla przewlekłej białaczki limfocytowej w 2025 roku — Raport Grupy Roboczej PTHiT i PALG-CLL. Hematologia — Edukacja. https://doi.org/10.5603/ahp.106584
Vancouver
Hus I, Giannopoulos K, Jamroziak K, Wołowiec D, Roliński J, Robak T. Rekomendacje diagnostyczne i terapeutyczne dla przewlekłej białaczki limfocytowej w 2025 roku — Raport Grupy Roboczej PTHiT i PALG-CLL. Hematologia — Edukacja. 2025. doi:10.5603/ahp.106584
BibTeX
@article{Hus2025,
author = {Hus, Iwona and Giannopoulos, Krzysztof and Jamroziak, Krzysztof and Wołowiec, Dariusz and Roliński, Jacek and Robak, Tadeusz},
title = {Rekomendacje diagnostyczne i terapeutyczne dla przewlekłej białaczki limfocytowej w 2025 roku — Raport Grupy Roboczej PTHiT i PALG-CLL},
journal = {Hematologia — Edukacja},
year = {2025},
doi = {10.5603/ahp.106584}
}
EUVIMED